• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Combination of early docetaxel therapy linked to increased survival in metastatic prostate cancer patients

byShaidah Deghan, MSc. MD
August 6, 2015
in Gastroenterology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adding six cycles of docetaxel to a standard Androgen-deprivation therapy (ADT) therapy resulted in significantly longer overall survival outcomes compared to the standard ADT-alone therapy.

2. The clinical benefit appears to be greater in patients with a higher burden of disease. Further investigations are warranted.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: ADT has been the main therapy for metastatic prostate cancer for decades. However, resistance to the therapy is common and survival in these patients is approximately 3 years. Subsequently, docetaxel can be used which compared to other treatments, such as mitoxantrone and prednisone, has shown an approximate 2.5 month longer survival.

This randomized controlled trial specifically investigated whether initiating docetaxel therapy at the beginning of ADT therapy for metastatic hormone-sensitive prostate cancer would result in longer overall survival compared to ADT treatment alone. 790 patients underwent randomization. The combination group demonstrated significantly better cancer control, longer time to castration resistance development, higher rate of decrease in the PSA to less than 0.2 ng/ml levels at 12 months, and overall longer survival compared to the ADT-alone group. In a subgroup analysis of patients with high-volume disease, the combination therapy group had an overall 17.0 month longer overall survival compared to the ADT-alone group.

Click to read the study, published today in NEJM

Relevant Reading: Systemic review and meta-analysis of monotherapy compared with combined androgen blockage for patients with advanced prostate carcinoma

RELATED REPORTS

Active monitoring, prostatectomy, and radiotherapy as treatment options for localized prostate cancer result in similar prostate-cancer-mortality

Plant-based diets may be associated with lower risk of aggressive prostate cancer

Wellness Check: Nutrition

In-Depth [randomized controlled trial]: The participants were enrolled by ECOG-ACRIN. 790 men aged 36 to 91 were enrolled in either the ADT plus docetaxel group or the ADT-alone group. There were no significant differences between the two groups for baseline patient characteristics. The early docetaxel and ADT group had an overall 13.6 month longer survival compared to the ADT alone group (57.6 months vs. 44.0 months; HR for death in combination group, 0.61; 95% [CI] 0.47 to 0.80; p<0.001). The patients in the combination group demonstrated a significantly lower PSA level to less than 0.2 ng/mL at 12 months compared to the ADT alone group (27.7% vs. 16.8%; p<0.001). The combination group developed resistance significantly later compared to the ADT-alone group (20.2 months vs. 11.7 months; HR 0.61; 95% [CI] 0.51 to 0.72; p<0.001).

The overall survival was more noticeable in the high-volume disease than in the overall study population. This population showed an overall 17.0 month longer survival in the combination group than in the ADT-alone group (49.2 months vs. 32.2 months; HR for death, 0.60; 95% [CI], 0.45 to 0.81; p< 0.001).

Reported adverse events of the combination therapy included: grade 3 or 4 allergic reaction, diarrhea, stomatitis, motor and sensory neuropathy, thromboembolic event, neutropenic fever, and infection with neutropenia.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: prostate cancer
Previous Post

Even low levels of physical activity reduce mortality in elderly

Next Post

Topical intracoital tenofovir gel linked to decreased incidence of herpes simplex virus type 2

RelatedReports

Oncology

Active monitoring, prostatectomy, and radiotherapy as treatment options for localized prostate cancer result in similar prostate-cancer-mortality

March 20, 2023
Vegetarian diet may lower incidence of colorectal cancer
Lifestyle

Plant-based diets may be associated with lower risk of aggressive prostate cancer

January 27, 2023
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

January 26, 2023
#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer
StudyGraphics

#VisualAbstract: Positive prostate MRI and targeted biopsy reduce the detection of clinically insignificant prostate cancer

January 4, 2023
Next Post
2 Minute Medicine Rewind January 13-19, 2014

Topical intracoital tenofovir gel linked to decreased incidence of herpes simplex virus type 2

Uninterrupted warfarin therapy safe for endovascular procedures

Uninterrupted warfarin therapy safe for endovascular procedures

Spicy food consumption linked to a reduction in mortality

Spicy food consumption linked to a reduction in mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options